Treatment Options for Grade 3 Invasive Ductal Carcinoma

Invasive ductal carcinoma (IDC) grade 3—also referred to as poorly differentiated or high-grade IDC—is the most aggressive histologic subtype of invasive breast cancer. Characterized by marked nuclear pleomorphism, frequent mitotic figures, and loss of glandular architecture, grade 3 tumors exhibit rapid proliferation and a higher propensity for local invasion and distant metastasis compared with lower-grade counterparts.

Management is multimodal and tailored to tumor biology, anatomic extent, and patient-specific factors such as age, comorbidities, and molecular receptor status. Standard treatment begins with surgical resection—either breast-conserving surgery (lumpectomy) followed by whole-breast radiotherapy, or mastectomy—depending on tumor size, multifocality, and patient preference. Sentinel lymph node biopsy is routinely performed; if positive, axillary lymph node dissection or targeted nodal irradiation may be indicated.

Systemic therapy is central to reducing recurrence risk. For hormone receptor–positive (HR+)/HER2-negative disease, adjuvant endocrine therapy—typically tamoxifen for premenopausal women or aromatase inhibitors for postmenopausal patients—is administered for 5 to 10 years. In HR+/HER2-positive cases, dual blockade with anti-HER2 agents (e.g., trastuzumab plus pertuzumab) is combined with chemotherapy and extended endocrine therapy. For triple-negative breast cancer (TNBC), neoadjuvant or adjuvant platinum-based or anthracycline/taxane-containing regimens are standard; in early-stage, high-risk TNBC, adjuvant capecitabine may be considered following completion of primary chemotherapy.

Neoadjuvant systemic therapy is increasingly favored for clinically stage II–III grade 3 IDC, particularly when downstaging is needed to enable breast conservation or to assess in vivo tumor response—pathologic complete response (pCR) being a strong surrogate for improved long-term outcomes. Emerging strategies include immunotherapy for PD-L1–positive TNBC in the neoadjuvant setting (e.g., pembrolizumab added to chemotherapy), and antibody–drug conjugates like trastuzumab deruxtecan for HER2-low disease.

Ongoing genomic profiling—including Oncotype DX, MammaPrint, or Prosigna—helps refine prognosis and guide decisions about chemotherapy escalation or de-escalation, especially in intermediate-risk HR+ cases. Close surveillance with clinical examination, annual mammography (and supplemental MRI in select high-risk individuals), and symptom-directed imaging remains essential, given the elevated risk of locoregional recurrence and contralateral disease in grade 3 IDC.